The Story of OncoRix

Oncorix was created as a result of realizing that almost 70% of cancer patients combine integrative therapies with the drugs prescribed by their doctors, and about a third of cancer patients believe that integrative therapies help them better treat their cancer, and not just the side effects.

We realized that the demand for integrative oncology is huge and growing, but doctors and patients lack sufficient support information to determine which solutions are best suited for their personal oncology journeys.

As part of our mission to bring extraordinary solutions to cancer, we formed a team of scientists in 2019. Oncology experts were drawn from pharmaceutical development and production as well as hospitals. During the discussion about ONCORIX’s next steps, it became more evident to the group how important integrative treatments and improving quality of life are for success. As the group realized, they did not need to get approval for a prescription drug, but to develop a leading oncology product that is deeply based in science and accepted by oncologists.

The company decided to focus on the active substances cannabinoids and medicinal mushrooms, which have a lot of scientific support. Around 50% of cancer patients use these active substances in combination with drugs.

In the last four years, ONCORIX has invested approximately $7 million in formulating and conducting scientific research to prove its unique products’ safety and effectiveness (In-vitro, In-Vivo, Ex-Vivo).

As soon as the green light was received from the oncology team to proceed with administration to humans, the company decided to move forward with all its strength to produce the product in California USA in order to start commercial sales and observational clinical trials in early 2024.